Edap Tms (NASDAQ:EDAP) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

Edap Tms S.A. (NASDAQ:EDAP) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.02 and traded as high as $4.39. Edap Tms shares last traded at $4.39, with a volume of 52,999 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Edap Tms in a report on Monday, December 29th. Wall Street Zen raised shares of Edap Tms to a “hold” rating in a report on Saturday, February 7th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.50.

Edap Tms Price Performance

The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $150.68 million, a PE ratio of -7.07 and a beta of -0.19. The firm’s 50 day simple moving average is $4.21 and its 200 day simple moving average is $3.03.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Rock Springs Capital Management LP boosted its stake in shares of Edap Tms by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after purchasing an additional 16,500 shares during the period. Flax Pond Capital LLC purchased a new stake in Edap Tms in the 4th quarter valued at about $2,623,000. Leonteq Securities AG bought a new position in Edap Tms in the 4th quarter worth about $313,000. Kovack Advisors Inc. purchased a new position in shares of Edap Tms during the fourth quarter worth approximately $53,000. Finally, Financial Planning Navigators CORP purchased a new position in shares of Edap Tms during the fourth quarter worth approximately $33,000. Institutional investors own 62.74% of the company’s stock.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.